Invitae puts forth $1.4B worth acquisition deal for ArcherDX
Category: #headlines  By Pranali Mehta  Date: 2020-06-24
  • share
  • Twitter
  • Facebook
  • LinkedIn
Invitae puts forth $1.4B worth acquisition deal for ArcherDX

Genetic testing company Invitae is reportedly on its way to purchasing personalized cancer test developer ArcherDX. The deal is speculated to have been finalized at USD 1.4 billion.

As per sources familiar with the knowledge of the matter, ArcherDX, earlier this month, had announced that it had been filing for a Nasdaq IPO worth USD 100 million. However, it seems to have canceled the IPO and gone ahead to be acquired by Invitae. The deal valuation is apparently inclusive of the shares of Invitae, upfront cash, and future milestone payments. Both the companies are planning to integrate their tumor profiling, liquid biopsy, and genomics technologies through a single overarching service.

The transaction will apparently commence with USD 325 million in cash along with 30 million shares of Invitae common stock, as well as an additional 27 million shares linked to milestones. The boards of both the companies have given their approval for the deal and it is expected to gain closure in the next several months.

It has been speculated that Invitae, in order to carry out the takeover, has set up a strategic financing equipped with more than USD 400 million in commitments from investors, with Perceptive Advisors in the lead. Invitae will sell USD 275 million of the stock through a private placement, at a rate of USD 16.85 per share, aided by Deerfield Management, Farallon, Redmile Group, Driehaus Capital Management, Casdin Capital, Soleus Capital, Rock Springs Capital, and PBM Capital.

Sean George, Co-founder and CEO, Invitae, has been quoted to state that the company aims to aggregate all genetic tests worldwide into a single platform and bring comprehensive genetic information into mainstream medicine, and this acquisition is a major step in that direction.

Jason Myers, Co-founder and CEO, ArcherDX, has been quoted to state that the firm is thrilled to acquire Invitae and form a nerve center for therapy optimization, precision oncology, monitoring, and diagnostics, and gain the opportunity for accelerating shareholder value and patient care.

Source Credits: https://www.fiercebiotech.com/medtech/archerdx-drops-ipo-plans-favor-a-1-4b-takeover-by-invitae

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Pranali Mehta

Pranali Mehta    

Pranali Mehta boasts of over three years of experience as a content writer. Having completed her graduation in chemical engineering, she worked as safety & environment associate in a chemical company for a year. Harnessing her passion for writing however, Pranali deci...

Read More >>

More News By Pranali Mehta

EU closes in on banning targeted ads to avoid misuse of sensitive data
EU closes in on banning targeted ads to avoid misuse of sensitive data
By Pranali Mehta

The European Parliament recently approved the initial draft of a bill that prohibits targeted advertising based on sensitive data such as religious beliefs, sexual orientation, race, or ethnic origin. The bill especially aims to address big tech comp...

Ambulance aggregator StanPlus secures USD 20 Mn to scale its offerings
Ambulance aggregator StanPlus secures USD 20 Mn to scale its offerings
By Pranali Mehta

StanPlus, the Hyderabad-based online ambulance aggregator, has reportedly raised USD 20 million in debt and equity during a funding round that was spearheaded by HealthQuad, Kalaari Capital, as well as HealthX Capital Singapore.  The fundraisin...

R&D projects worth USD 5.5 Mn approved under India-Israel tech fund
R&D projects worth USD 5.5 Mn approved under India-Israel tech fund
By Pranali Mehta

As a part of discussions on expanding the reach of India Israel Industrial R&D along with Technological Innovation Fund, the two nations have approved three joint R&D projects costing USD 5.5 million and discussed methods to develop a bigger ...